Castleark Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Castleark Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-96,045	Closed	-$4.66M	–	344
2020 Q2	$4.66M	Sell	96,045 -117,025	-55%	-$5.62M	0.2%	129
2020 Q1	$9M	Sell	213,070 -2,700	-1%	-$111K	0.53%	52
2019 Q4	$9.23M	Buy	215,770 +23,700	+12%	+$1.03M	0.37%	88
2019 Q3	$6.91M	Buy	+192,070	New	+$5.82M	0.28%	126
2017 Q2	–	Sell	-206,980	Closed	-$7.12M	–	389
2017 Q1	$7.12M	Buy	+206,980	New	+$7.31M	0.22%	149

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Castleark Management's ACAD Position: Q3 2020 in Review

Castleark Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 96,045 shares — an estimated $4.66M sold.

Castleark Management first reported a position in ACAD in Q1 2017 and held it in 5 quarters. The position peaked at $9.23M in Q4 2019. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Castleark Management reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Castleark Management sold 96,045 Acadia Pharmaceuticals shares in Q3 2020, an estimated $4.66M.
Castleark Management first reported a position in Acadia Pharmaceuticals in Q1 2017 and held it in 5 quarters.
Castleark Management's Acadia Pharmaceuticals position peaked at $9.23M in Q4 2019.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Castleark Management's 13F filing for Q3 2020, filed 16 Nov 2020.